151257-03-3

Basic information

• Product Name: 2-n-butyl-1,3-diazaspiro<4.4>nonan-4-one
• Synonyms: 2-n-butyl-1,3-diazaspiro<4.4>nonan-4-one
• CAS NO: 151257-03-3
• Molecular Weight: 196.293
• Mol File: 151257-03-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-n-butyl-1,3-diazaspiro<4.4>nonan-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-n-butyl-1,3-diazaspiro<4.4>nonan-4-one(151257-03-3)
• EPA Substance Registry System: 2-n-butyl-1,3-diazaspiro<4.4>nonan-4-one(151257-03-3)

Safety Data

• Hazardous Substances Data: 151257-03-3(Hazardous Substances Data)

Upstream product

• 138402-05-8 2-butyl-1,3-diaza-spiro[4.4]non-1-en-4one 
• 110-62-3 pentanal 
• 17193-28-1 1-aminocyclopentane-1-carboxamide 
• 999-09-7 ethyl valerimidate 
• 1664-35-3 ethyl 1-aminocyclopentanecarboxylate 

Downstream Products

• 151257-04-4 tert-butyl-4'-<(2-n-butyl-4-oxo-1,3-diazaspiro<4.4>nonan-1-yl)methyl>biphenyl-2-carboxylate 
• 151257-05-5 tert-butyl-4'-<(2-n-butyl-4-oxo-1,3-diazaspiro<4.4>non-2-en-1-yl)methyl>biphenyl-2-carboxylate 
• 138402-05-8 2-butyl-1,3-diaza-spiro[4.4]non-1-en-4one 

Relevant articles and documents

Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening

Leuktriene B4 receptor 2 (BLT2) is a G-protein coupled receptor modulation of which is discussed to be a therapeutic option for healing of intestinal lesions. In this work, new BLT2 agonists were identified by a virtual screening of a repurposing library and in vitro assay of the most promising compounds. Irbesartan, an approved type-1 angiotensin II receptor (AT1) antagonist, was identified as a moderate BLT2 agonist. An initial SAR study on the irbesartan scaffold was performed resulting in the discovery of a new potent BLT2 agonist (8f, EC50 = 67.6 nM). Irbesartan and 8f were shown to promote proliferation of epithelial colon cells, an effect which was reversible by a BLT2 antagonist.

Process for the preparation of cyclic 4-oxoamidines

The present invention relates to a process for the preparation of cyclic 4-oxoamidines. Such substances are precursors of active substances having biological action. The process according to the invention forms a further method of obtaining this class of compound. By reacting condensation products of aldehydes and aminonitriles or amino acid amides with oxidizing agents, the desired cyclic 4-oxoamidines are obtained according to the invention in good to very good yields.